Abstract
Background
Administrative data are frequently used to identify venous thromboembolism (VTE) for research and quality reporting. However, the validity of these codes, particularly in outpatients, has not been well-established.
Objective
To determine how well ICD-9 codes for VTE predict chart-confirmed acute VTE in inpatient and outpatients.
Patients/Methods
We selected 4642 adults with an incident ICD-9 diagnosis of VTE between years 2004 and 2010 from the Cardiovascular Research Network Venous Thromboembolism cohort study. Medical charts were reviewed to determine validity of events. Positive predictive values (PPVs) of ICD-9 codes were calculated as the number of chart-validated VTE events divided by the number with specific VTE codes. Analyses were stratified by VTE type (pulmonary embolism, deep venous thrombosis [DVT]), code position (primary, secondary), and setting (hospital/emergency department [ED], outpatient).
Results
The PPV for any diagnosis of VTE was 64.6% for hospital/ED patients and 30.9% for outpatients. Primary diagnosis codes from hospital/ED patients were more likely to represent acute VTE than secondary diagnosis codes (78.9% vs. 44.4%, p<0.001). Primary hospital/ED codes for pulmonary embolism and lower extremity DVT had higher PPV than for upper extremity DVT (89.1%, 74.9%, and 58.1%, respectively). Outpatient codes were poorly predictive of acute VTE: 28.0% for pulmonary embolism and 53.6% for lower extremity DVT.
Conclusions
ICD-9 codes for VTE obtained from outpatient encounters or from secondary diagnosis codes do not reliably reflect acute VTE. More accurate ways of identifying VTE in outpatients are needed before these codes can be adopted for research or policy purposes.
Background
Venous thromboembolism (VTE) is a major public health problem in the United States, affecting an estimated 300,000 to 600,000 people nationally each year[1–3]. Due to the significant morbidity and mortality resulting from pulmonary embolism (PE) and deep venous thrombosis (DVT), VTE has become a target for active surveillance and quality reporting[2, 4–6]. Governmental and regulatory agencies such as the Agency for Healthcare Research and Quality, the Joint Commission, and the Centers for Medicare & Medicaid Services (CMS) have adopted measures of VTE to assess hospital quality[7, 8]. Identifying VTE events for the purposes of quality reporting and research relies heavily on the use of administrative codes, primarily using International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes[1, 5, 9]. However, the validity of using ICD-9 codes to identify VTE events remains questionable[5]. While some studies have found that ICD-9 codes are reasonably concordant with medical chart review, others have found much lower rates of validity, and rates that vary by the type and position of the code[5, 10–13].
Moreover, most studies addressing the validity of VTE ICD-9 codes have been conducted only in hospital or post-operative settings and in earlier treatment eras. As the diagnosis and management of VTE moves increasingly to the outpatient arena, it is vital to determine whether outpatient VTE codes are reliable proxies for true clinical events before these diagnostic codes can be depended on for research, policy and quality reporting purposes. The objective of our multicenter study was to examine the validity of VTE ICD-9 diagnosis codes in both inpatient and outpatient settings based on medical chart review.
Methods
Identification of potential VTE events
We obtained clinical and administrative data from four integrated healthcare delivery systems that participated in the Cardiovascular Research Network Venous Thromboembolism (CVRN VTE) study. The four systems represented diverse geographic health plan members from: Kaiser Permanente Northern California, which during the study period served >3.2 million members in Northern California; Kaiser Permanente Colorado, which served >460,000 members in the Denver, Colorado metropolitan area; Marshfield Clinic, which served >550,000 members in central and northwest Wisconsin; and Geisinger Health System, which served approximately 2.5 million members in central and northwest Pennsylvania.
We included adult health plan members (age ≥ 21 years) who were enrolled for at least 12 months and with continuous pharmacy benefits, who had a least one clinical encounter with a diagnosis code for VTE during the time period October 1, 2004 through December 31, 2010. The index VTE event was defined as the first encounter associated with a VTE diagnosis code during the study time period. In order to focus on incident VTE events, we excluded patients with a prior diagnostic code for VTE while enrolled in the health plan, or who were prescribed relevant anticoagulants, within 4 years of the index event.
VTE codes were categorized as pulmonary embolism (ICD-9 code 415.1x), lower extremity DVT (451.1x, 451.2, 451.81, 453.4x, 453.5x), upper extremity DVT (451.83, 451.84, 451.89, 453.72, 453.73, 453.74, 453.75, 453.76, 453.77, 453.82, 453.83, 453.84, 453.85, 453.86, 453.87), and other venous thrombosis (451, 451.9, 452, 453, 453.0, 453.1, 453.2, 453.3, 453.79, 453.8, 453.89, 453.9). Codes for pregnancy-related VTE and superficial thrombophlebitis were not included in this study. All encounters with a VTE diagnosis were included in the search, including from hospital, emergency department (ED), and outpatient settings.
Validation of VTE events
Out of 42,941 individuals with an index VTE encounter, 5,264 were selected for manual medical record review. For two of the sites, all available charts with a VTE encounter were reviewed. For the other two sites, a random sample of the charts were selected for review due to the large number of potential events. Electronic medical record systems were available at all clinical sites during the time period of the study. Research staff obtained all available hospital admission, transfer, and discharge notes, as well as emergency department notes, outpatient encounter notes, and relevant radiology reports within 72 hours before and after the VTE encounter date. Records were then reviewed by trained physician and pharmacist reviewers who used a structured data abstraction tool to determine whether encounters represented valid, acute VTE events. An event was considered to be valid if there was radiologic, operative, or autopsy evidence of acute VTE, or if a physician documented in the medical record that an acute VTE occurred during that episode of care. VTE events whose acute management was not contiguous with the current episode (such as patients with a history of previously treated VTE) were not considered valid events. Superficial venous thrombophlebitis was not considered to be a valid VTE.
If a reviewer determined that the encounter did not represent a valid, acute VTE, he/she then categorized the event as one of the following: past history of VTE but not an acute event, superficial venous thrombophlebitis, non-VTE alternative diagnosis, “rule-out VTE” (where VTE was suspected but the diagnostic test was negative), or insufficient information in the medical documentation to confirm an acute VTE event.
Subject characteristics
Characteristics of the subjects were obtained from clinical and administrative databases, including demographic features (age, gender, race and ethnicity) and coexisting medical conditions identified by the presence of relevant ICD-9 diagnosis codes up to 4 years prior to the index VTE event. Anticoagulant use was ascertained by searching health plan pharmacy databases for filled outpatient prescriptions for anticoagulants within 7 days of the VTE encounter. Anticoagulants were categorized as oral (warfarin sodium) or parenteral (low-molecular-weight-heparins and fondaparinux). During the time period of the study, the target-specific oral anticoagulants such as dabigatran, rivaroxaban, apixaban, and edoxaban were not yet approved by the US Food and Drug Administration for use in acute VTE and so were not included.
Statistical analysis
All analyses were conducted using SAS statistical software version 9.1 (Cary, NC). We reported the positive predictive value of specific VTE codes compared to medical record review. Positive predictive value was calculated as the number of valid VTE events divided by the total number of patients within a set of VTE diagnosis codes. Subjects whose clinical documentation was unavailable for chart review were excluded from the analysis. We examined whether positive predictive value varied according to VTE-type (i.e., PE, lower extremity DVT, upper extremity DVT, and other venous thrombosis), clinical setting (hospital/ED versus outpatient), and, for hospital/ED encounters, by position of the code (primary versus secondary). We did not distinguish between primary or secondary code positions for outpatient encounters, as outpatient visits frequently do not have a single, leading diagnosis. We then tested whether the positive predictive value of diagnosis codes changed when we included a criterion of a filled prescription for anticoagulant within 7 days of the VTE encounter. Finally, we tested whether there were changes in positive predictive value after October 9, 2009, when additional VTE codes became available to further specify superficial venous thrombophlebitis, chronic VTE, and upper extremity VTE[14].
This study was approved by the institutional review boards of the participating institutions and waiver of informed consent was obtained due to the nature of the study.
Results
We reviewed the medical charts of 5,264 subjects who had an encounter with a VTE diagnosis code during the study time period and who met study eligibility criteria. Clinical characteristics of these individuals are presented in Table 1. A total of 622 encounters lacked clinical documentation related to the VTE episode and were excluded from the analysis. The final analytic cohort therefore comprised 4,642 individual patient encounters, of which 2,890 were hospital/ED encounters and 1,752 outpatient encounters.
Table 1.
Subject Characteristics | Hospital/Emergency Department (N=3175) | Outpatient (N=2089) | P-Value* | Overall (N=5264) |
---|---|---|---|---|
| ||||
n (%)
|
||||
Age, yrs | <0.001 | |||
21–49 | 503 (15.8) | 434 (20.8) | 937 (17.8) | |
50–59 | 478 (15.1) | 448 (21.4) | 926 (17.6) | |
60–69 | 700 (22.0) | 465 (22.3) | 1165 (22.1) | |
70–79 | 849 (26.7) | 464 (22.2) | 1313 (24.9) | |
≥ 80 | 645 (20.3) | 278 (13.3) | 923 (17.5) | |
Women | 1639 (51.6) | 1238 (59.3) | 2877 (54.7) | |
Race | <0.001 | |||
White/European | 2543 (80.1) | 1574 (75.3) | 4117 (78.2) | |
Black/African-American | 123 (3.9) | 73 (3.5) | 196 (3.7) | |
Asian/Pacific Islander | 22 (0.7) | 17 (0.8) | 39 (0.7) | |
Other/Unknown | 487 (15.3) | 425 (20.3) | 912 (17.3) | |
Hispanic ethnicity | <0.001 | |||
Hispanic | 154 (4.9) | 94 (4.5) | 248 (4.7) | |
Non-Hispanic | 2203 (69.4) | 1334 (63.9) | 3537 (67.2) | |
Unknown | 818 (25.8) | 661 (31.6) | 1479 (28.1) | |
Diagnosis in primary position | <0.001 | |||
Pulmonary embolism | 976 (30.7) | 87 (4.2) | 1063 (20.2) | |
Lower extremity DVT | 583 (18.4) | 369 (17.7) | 952 (18.1) | |
Upper extremity DVT | 35 (1.1) | 29 (1.4) | 64 (1.2) | |
Other venous thrombosis | 271 (8.5) | 583 (27.9) | 854 (16.2) | |
Diagnosis in secondary position | <0.001 | |||
Pulmonary embolism | 384 (12.1) | 222 (10.6) | 606 (11.5) | |
Lower extremity DVT | 388 (12.2) | 266 (12.7) | 654 (12.4) | |
Upper extremity DVT | 101 (3.2) | 30 (1.4) | 131 (2.5) | |
Other venous thrombosis | 437 (13.8) | 503 (24.1) | 940 (17.9) | |
Filled anticoagulant prescription within 7 days | 1513 (47.7) | 536 (25.7) | <0.001 | 2049 (38.9) |
Medical chart unavailable for review | 285 (9.0) | 337 (16.1) | <0.001 | 622 (11.8) |
Medical diagnoses | ||||
Hypertension | 1998 (62.9) | 1114 (53.3) | <0.001 | 3112 (59.1) |
Diabetes mellitus | 834 (26.3) | 404 (19.3) | <0.001 | 1238 (23.5) |
Systemic cancer | 1113 (35.1) | 592 (28.3) | <0.001 | 1705 (32.4) |
Prior ischemic stroke | 99 (3.1) | 52 (2.5) | 0.18 | 151 (2.9) |
Coronary heart disease | 304 (9.6) | 149 (7.1) | <0.01 | 453 (8.6) |
Chronic heart failure | 467 (14.7) | 191 (9.1) | <0.001 | 658 (12.5) |
Chronic lung disease | 878 (27.7) | 386 (18.5) | <0.001 | 1264 (24.0) |
Chronic liver disease | 138 (4.3) | 67 (3.2) | <0.05 | 205 (3.9) |
Inflammatory bowel disease | 71 (2.2) | 28 (1.3) | <0.05 | 99 (1.9) |
Diagnosed thrombophilia | 19 (0.6) | 38 (1.8) | <0.001 | 57 (1.1) |
Acute sepsis | 162 (5.1) | 36 (1.7) | <0.001 | 198 (3.8) |
P value comparison between hospital/emergency department and outpatient
Positive predictive value of VTE codes
The overall positive predictive value of any VTE code, inpatient or outpatient, was 51.9% and varied widely by clinical setting and VTE type (Table 2). Primary discharge diagnosis codes for PE, and to a lesser degree, lower extremity DVT, obtained from a hospital/ED encounter had reasonably high positive predictive values (89.1% and 74.9%, respectively). Outpatient codes on the other hand were unlikely to represent acute VTE; the highest positive predictive value in outpatients was for lower extremity DVT, which reflected chart-confirmed events only 53.6% of the time (Table 2).
Table 2. The Positive Predictive Value of VTE Codes Based on Medical Records Review, Stratified by Encounter Setting and Position of Code (n=4642).
Hospital/Emergency Department N=2890 |
Outpatient N=1752 |
||
---|---|---|---|
| |||
Primary Position N=1696 |
Secondary Position N=1194 |
||
|
|||
Any VTE code | 78.9% (1338/1696) | 44.4% (530/1194) | 30.9% (542/1752) |
Pulmonary embolism codes 415.1x |
89.1% (800/909) | 55.8% (196/351) | 28.0% (74/264) |
Lower extremity DVT codes 451.1x, 451.2, 451.81, 453.4x, 453.5x |
74.9% (387/517) | 50.1% (179/357) | 53.6% (297/554) |
Upper extremity DVT codes 451.83, 451.84, 451.89, 453.72, 453.73, 453.74, 453.75, 453.76, 453.77, 453.82, 453.83, 453.84, 453.85, 453.86, 453.87 |
58.1% (18/31) | 31.1% (28/90) | 6.5% (3/46) |
Other venous thrombosis codes 451, 451.9, 452, 453, 453.0, 453.1, 453.2, 453.3, 453.79, 453.8, 453.89, 453.9 |
55.6% (133/239) | 32.1% (127/396) | 18.9% (168/888) |
When we restricted the analysis to the 1,974 patients who had an anticoagulant prescription within 7 days after being discharged from the VTE encounter, the positive predictive value for VTE increased for both inpatients and outpatients (87.6% and 75.5%, respectively, Table 3). Using the criteria of anticoagulant prescription did, however, miss a substantial number of patients with valid VTE: out of the 2410 patients with chart-validated VTE, 744 (30.9%) did not have a filled anticoagulant prescription. Of the 2410 patients, 146 (20%) had a diagnosis or procedure code for interruption of the vena cava within 3 days of the encounter end. Extending the ascertainment period for anticoagulant prescription to 30 days did not change the results substantively, with 644 (26.7%) of patients lacking a filled anticoagulant prescription.
Table 3. The Positive Predictive Value of VTE Codes + Anticoagulant Prescriptions Compared to Medical Chart Review (n=1974).
Hospital/Emergency Department N=1451 |
Outpatient N=523 |
||
---|---|---|---|
| |||
Primary Position N=1080 |
Secondary Position N=371 |
||
|
|||
Any VTE code | 92.4% (998/1080) | 73.6% (273/371) | 75.5% (395/523) |
Pulmonary embolism codes 415.1x |
95.4% (617/647) | 84.8% (117/138) | 54.5% (55/101) |
Lower extremity DVT codes 451.1x, 451.2, 451.81, 453.4x, 453.5x |
89.6% (276/308) | 71.6% (83/116) | 89.7% (234/261) |
Upper extremity DVT codes 451.83, 451.84, 451.89, 453.72, 453.73, 453.74, 453.75, 453.76, 453.77, 453.82, 453.83, 453.84, 453.85, 453.86, 453.87 |
81.8% (9/11) | 55.2% (16/29) | 100% (2/2) |
Other venous thrombosis codes 451, 451.9, 452, 453, 453.0, 453.1, 453.2, 453.3, 453.79, 453.8, 453.89, 453.9 |
84.2% (96/114) | 64.8% (57/88) | 65.4% (104/159) |
When we examined the positive predictive value of individual diagnosis codes, several codes were especially poor predictors of acute VTE (Table 4). In particular, codes denoting phlebitis or thrombophlebitis, even of specified deep veins, had low positive predictive values, as did codes for “other venous thrombosis” (Table 4). When we compared the positive predictive value of VTE codes pre-October 2009 and post-October 2009, the largest change was seen in the predictive value of hospital/ED diagnostic codes for upper extremity DVT, where the positive predictive value of a primary diagnosis code of upper extremity DVT increased from 31.3% to 86.7%, and from 18.3% to 56.7% for a codes in a secondary position.
Table 4.
Code | Definition | Hospital/Emergency Department | Outpatient |
---|---|---|---|
Pulmonary embolism | |||
| |||
415.1 | Pulmonary embolism and infarction | 0.0% (0/1) | n/a |
415.11 | Iatrogenic pulmonary embolism and infarction | 79.0% (64/81) | 28.6% (2/7) |
415.19 | Other pulmonary embolism and infarction | 79.1% (932/1178) | 28.0% (72/257) |
| |||
Lower extremity DVT | |||
| |||
451.11 | Phlebitis and thrombophlebitis of femoral vein | 10.7% (3/28) | 8.3% (1/12) |
451.19 | Phlebitis and thrombophlebitis of deep veins of lower extremities, other | 36.4% (24/66) | 38.5% (40/104) |
451.2 | Phlebitis and thrombophlebitis of lower extremities, unspecified | 7.1% (2/28) | 8.8% (3/34) |
451.81 | Phlebitis and thrombophlebitis of iliac vein | 50.0% (1/2) | n/a |
453.40 | Venous embolism and thrombosis of unspecified deep vessels of lower extremity | 58.8% (190/323) | 61.1% (187/306) |
453.41 | Acute venous embolism and thrombosis of deep vessels of proximal lower extremity | 83.6% (199/238) | 80.9% (38/47) |
453.42 | Acute venous embolism and thrombosis of deep vessels of distal lower extremity | 79.7% (145/182) | 56.3% (27/48) |
453.5 | Chronic venous embolism and thrombosis of deep vessels of lower extremity | 0.0% (0/4) | 50.0% (1/2) |
453.51 | Chronic venous embolism and thrombosis of deep vessels of proximal lower extremity | 50.0% (1/2) | 0.0% (0/1) |
453.52 | Chronic venous embolism and thrombosis of deep vessels of distal lower extremity | 100% (1/1) | n/a |
| |||
Upper extremity DVT | |||
| |||
451.83 | Phlebitis and thrombophlebitis of deep veins of upper extremities | 71.4% (10/14) | 0.0% (0/3) |
451.84 | Phlebitis and thrombophlebitis of upper extremities, unspecified | 3.9% (2/51) | 0.0% (0/22) |
451.89 | Phlebitis and thrombophlebitis of other upper extremity site | 40.7% (11/27) | 10.5% (2/19) |
453.72 | Chronic venous embolism and thrombosis of deep veins of upper extremity | 100% (2/2) | n/a |
453.73 | Chronic venous embolism and thrombosis of upper extremity, unspecified | n/a | n/a |
453.74 | Chronic venous embolism and thrombosis of axillary veins | n/a | n/a |
453.75 | Chronic venous embolism and thrombosis of subclavian veins | 0.0% (0/1) | n/a |
453.76 | Chronic venous embolism and thrombosis of subclavian veins | n/a | 0.0% (0/1) |
453.77 | Chronic venous embolism and thrombosis of other thoracic veins | n/a | n/a |
453.82 | Acute venous embolism and thrombosis of deep veins of upper extremity | 100% (4/4) | 100% (1/1) |
453.83 | Acute venous embolism and thrombosis of deep veins of upper extremity | 60.0% (3/5) | n/a |
453.84 | Acute venous embolism and thrombosis of axillary veins | 80.0% (4/5) | n/a |
453.85 | Acute venous embolism and thrombosis of subclavian veins | 100% (5/5) | n/a |
453.86 | Acute venous embolism and thrombosis of internal jugular veins | 50.0% (2/4) | n/a |
453.87 | Acute venous embolism and thrombosis of other thoracic veins | 100% (3/3) | n/a |
| |||
Other venous thrombosis | |||
| |||
451.9 | Phlebitis and thrombophlebitis of unspecified site | 12.9% (4/31) | 4.0% (12/303) |
452 | Portal vein thrombosis | 58.5% (38/65) | 42.9% (9/21) |
453.0 | Budd-Chiari syndrome | 11.1% (1/9) | 0.0% (0/1) |
453.1 | Thrombophlebitis migrans | n/a | 0.0% (0/1) |
453.2 | Other venous embolism and thrombosis of inferior vena cava | 62.5% (10/16) | 33.3% (1/3) |
453.3 | Other venous embolism and thrombosis of renal vein | 66.7% (4/6) | 33.3% (1/3) |
453.79 | Chronic venous embolism and thrombosis of other specified veins | 50.0% (1/2) | n/a |
453.8 | Acute venous embolism and thrombosis of other specified veins | 47.9% (172/359) | 31.1% (118/379) |
453.89 | Acute venous embolism and thrombosis of other specified veins | 20.0% (1/5) | 0.0% (0/2) |
453.9 | Other venous embolism and thrombosis of unspecified site | 20.4% (29/142) | 15.4% (27/175) |
Reasons encounters with VTE codes were not considered valid VTE events
There were 2,606 encounters that after review were not considered valid VTE events. The reasons for being coded as invalid varied widely by setting and VTE type (Table 5). For hospital/ED encounters, alternative non-VTE diagnoses were the most common reasons for not being considered valid. In outpatient encounters, codes for PE or lower extremity DVT often reflected a past history of VTE. Patients with an upper extremity DVT code were frequently determined to have superficial venous thrombophlebitis after chart review (Table 5).
Table 5.
Reason why events were not considered valid | Hospital/Emergency Department (N=1229)
|
|||
---|---|---|---|---|
Pulmonary embolism N=338 |
Lower extremity DVT N=379 |
Upper extremity DVT N=88 |
Other venous thrombosis N=424 |
|
Prior history of VTE but not acute | 14.2% (48/338) | 15.6% (59/379) | 5.7% (5/88) | 9.4% (40/424) |
Alternative non-VTE diagnosis | 43.8% (148/338) | 38.0% (144/379) | 39.8% (35/88) | 46.5% (197/424) |
Superficial venous thrombophlebitis | 2.1% (7/338) | 13.5% (51/379) | 25.0% (22/88) | 14.9% (63/424) |
Initial concern for VTE but subsequently excluded | 19.2% (65/338) | 15.3% (58/379) | 4.5% (4/88) | 10.6% (45/424) |
VTE suspected, but not confirmed | 3.6% (12/338) | 0% (0/379) | 0% (0/88) | 0.5% (2/424) |
Insufficient documentation available in chart | 17.2% (58/338) | 17.7% (67/379) | 25.0% (22/88) | 18.2% (77/424) |
Reason why events were not considered valid | Outpatient Encounters (N=1377)
|
|||
---|---|---|---|---|
Pulmonary embolism N=213 |
Lower extremity DVT N=303 |
Upper extremity DVT N=49 |
Other venous thrombosis N=812 |
|
Prior history of VTE but not acute | 68.1% (145/213) | 35.0% (106/303) | 2.0% (1/49) | 15.8% (128/812) |
Alternative non-VTE diagnosis | 18.8% (40/213) | 24.8% (75/303) | 22.4% (11/49) | 22.3% (181/812) |
Superficial venous thrombophlebitis | 2.3% (5/213) | 12.9% (39/303) | 51.0% (25/49) | 44.7% (363/812) |
Initial concern for VTE but subsequently excluded | 4.7% (10/213) | 16.5% (50/303) | 4.1% (2/49) | 7.0% (57/812) |
VTE suspected, but not confirmed | 0% (0/213) | 0% (0/303) | 0% (0/49) | 0.2% (2/812) |
Insufficient documentation available in chart | 6.1% (13/213) | 10.9% (33/303) | 20.4% (10/49) | 10.0% (81/812) |
Discussion
Our study found that ICD-9 codes for PE in a primary position during a hospital or ED encounter accurately reflected acute VTE nearly 90% of the time when compared to chart review. However, codes for other types of VTE, and codes that were in the secondary position or from an outpatient encounter, were much less likely to represent acute VTE.
The validity of VTE ICD-9 codes increased when we added the criteria of an anticoagulant prescription dispensed shortly after discharge, and linking the presence of an ICD-9 code for VTE with an anticoagulant prescription may be one way to increase the likelihood that an event reflects a true acute VTE. The downside, however, of restricting to patients who received anticoagulants would be to inappropriately exclude approximately 30% of patients with valid VTE events who did not fill a prescription for anticoagulants within a week.
There was substantial variation in how well individual ICD-9 codes correlated with chart-confirmed VTE events. ICD-9 codes that were for phlebitis or thrombophlebitis (even of deep veins) or referred to unspecified or “other” locations, were in general poorly predictive of true VTE events. Although ICD-9 codes for phlebitis and thrombophlebitis have been used in prior studies of VTE and have also been adopted for quality reporting purposes, the results of our study argue that these codes are unlikely to represent true VTE events.
Our findings have significant implications for research and policies that rely on administrative codes for VTE[6]. Studies that use both inpatient and outpatient codes to identify VTE may be substantially overestimating the actual burden of disease[15, 16]. More parsimonious sets of codes, validation via chart review, or incorporating additional criteria, such as anticoagulant prescription, may help to improve the accuracy of using administrative data to identify actual VTE events. In 2007, CMS introduced present-on-admission (POA) indicator codes to help distinguish hospital-acquired events from pre-existing conditions. The use of POA codes appeared to improve identification of incident hospital-acquired VTE, but these codes were not always accurately applied[17]. In addition, POA codes are applicable only for acute hospitalizations and thus do not apply to outpatients, where the greatest need for accurate codes exists.
Our study had several limitations. Some codes were infrequently observed in our sample, including codes for venous thrombosis in unusual sites like the renal vein. We were unable to review the medical charts of 622 patients, and because unavailable medical charts were more often for outpatient encounters, it is possible that a review of these charts would have increased our estimated positive predictive value for outpatient VTE from its very low level of 30.9%. However, we note that even if all missing charts were considered to be valid VTE events, the predictive value of outpatient codes would not be high enough for policy and research applications. Finally, an expanded set of VTE codes was introduced in October 2009, most notably to help delineate chronic from acute VTE and superficial from deep venous thrombosis. While we found some modest effects, others have reported much higher positive predictive values associated with the use of these codes[14]. As these codes were only available for slightly more than one year of our study period, it is possible that accuracy of inpatient VTE codes has improved even more since then.
Administrative databases are increasingly used for outcomes research and quality measurement in VTE. It is important to acknowledge the limitations of using such databases. Outpatient VTE codes, in particular, should not currently be relied upon to provide accurate representations of acute VTE and additional ways to confirm VTE events in outpatients are needed.
References
- 1.Yusuf HR, Reyes N, Zhang QC, Okoroh EM, Siddiqi AE, Tsai J. Hospitalizations of adults >/=60 years of age with venous thromboembolism. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2014;20:136–42. doi: 10.1177/1076029613493659. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. American journal of preventive medicine. 2010;38:S495–501. doi: 10.1016/j.amepre.2009.12.017. [DOI] [PubMed] [Google Scholar]
- 3.The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. Rockville (MD): 2008. [PubMed] [Google Scholar]
- 4.Bilimoria KY, Chung J, Ju MH, Haut ER, Bentrem DJ, Ko CY, Baker DW. Evaluation of surveillance bias and the validity of the venous thromboembolism quality measure. JAMA. 2013;310:1482–9. doi: 10.1001/jama.2013.280048. [DOI] [PubMed] [Google Scholar]
- 5.Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data. Pharmacoepidemiology and drug safety. 2012;21(Suppl 1):154–62. doi: 10.1002/pds.2341. [DOI] [PubMed] [Google Scholar]
- 6.Raskob GE, Silverstein R, Bratzler DW, Heit JA, White RH. Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. American journal of preventive medicine. 2010;38:S502–9. doi: 10.1016/j.amepre.2010.01.010. [DOI] [PubMed] [Google Scholar]
- 7.AHRQ QI Research Version 50, Patient Safety Indicators 12, Technical Specifications. 2015. Perioperative Pulmonary Embolism or Deep Vein Thrombosis Rate: Technical Specifications. [Google Scholar]
- 8.The Centers for Medicare & Medicaid Services and The Joint Commission. Specifications Manual for National Hospital Inpatient Quality Measures Versions 4.4a. 2015. [Google Scholar]
- 9.Vartak S, Ward MM, Vaughn TE. Do postoperative complications vary by hospital teaching status? Medical care. 2008;46:25–32. doi: 10.1097/MLR.0b013e3181484927. [DOI] [PubMed] [Google Scholar]
- 10.White RH, Sadeghi B, Tancredi DJ, Zrelak P, Cuny J, Sama P, Utter GH, Geppert JJ, Romano PS. How valid is the ICD-9-CM based AHRQ patient safety indicator for postoperative venous thromboembolism? Med Care. 2009;47:1237–43. doi: 10.1097/MLR.0b013e3181b58940. [DOI] [PubMed] [Google Scholar]
- 11.Lau BD, Haut ER, Hobson DB, Kraus PS, Maritim C, Austin JM, Shermock KM, Maheshwari B, Allen PX, Almario A, Streiff MB. ICD-9 Code-Based Venous Thromboembolism Performance Targets Fail to Measure Up. Am J Med Qual. 2015 doi: 10.1177/1062860615583547. [DOI] [PubMed] [Google Scholar]
- 12.Zhan C, Battles J, Chiang YP, Hunt D. The validity of ICD-9-CM codes in identifying postoperative deep vein thrombosis and pulmonary embolism. Joint Commission journal on quality and patient safety / Joint Commission Resources. 2007;33:326–31. doi: 10.1016/s1553-7250(07)33037-7. [DOI] [PubMed] [Google Scholar]
- 13.White RH, Garcia M, Sadeghi B, Tancredi DJ, Zrelak P, Cuny J, Sama P, Gammon H, Schmaltz S, Romano PS. Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. Thrombosis research. 2010;126:61–7. doi: 10.1016/j.thromres.2010.03.009. [DOI] [PubMed] [Google Scholar]
- 14.Sadeghi B, White RH, Maynard G, Zrelak P, Strater A, Hensley L, Cerese J, Romano P. Improved coding of postoperative deep vein thrombosis and pulmonary embolism in administrative data (AHRQ Patient Safety Indicator 12) after introduction of new ICD-9-CM diagnosis codes. Medical care. 2015;53:e37–40. doi: 10.1097/MLR.0b013e318287d59e. [DOI] [PubMed] [Google Scholar]
- 15.Tsai J, Grant AM, Beckman MG, Grosse SD, Yusuf HR, Richardson LC. Determinants of venous thromboembolism among hospitalizations of US adults: a multilevel analysis. PloS one. 2015;10:e0123842. doi: 10.1371/journal.pone.0123842. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Deitelzweig SB, Johnson BH, Lin J, Schulman KL. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. American journal of hematology. 2011;86:217–20. doi: 10.1002/ajh.21917. [DOI] [PubMed] [Google Scholar]
- 17.Khanna RR, Kim SB, Jenkins I, El-Kareh R, Afsarmanesh N, Amin A, Sand H, Auerbach A, Chia CY, Maynard G, Romano PS, White RH. Predictive value of the present-on-admission indicator for hospital-acquired venous thromboembolism. Medical care. 2015;53:e31–6. doi: 10.1097/MLR.0b013e318286e34f. [DOI] [PubMed] [Google Scholar]